Search

Your search keyword '"Schouten, Harry C."' showing total 813 results
Start Over Author "Schouten, Harry C."
813 results on '"Schouten, Harry C."'

101. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

Author

Doorduijn, Jeanette K., Imhoff, Gustaaf W. van, Holt, Bronno van der, Schouten, Harry C., Schaafsma, Martijn R., MacKenzie, M.A., Poortmans, P.M.P., and Bromberg, Jacoline E.C.

Subjects
All institutes and research themes of the Radboud University Medical Center, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Women's cancers Radboud Institute for Health Sciences [Radboudumc 17]
Abstract

Item does not contain fulltext

Published
2017

102. Impact of Three Courses of Intensified CHOP Prior to High-Dose Sequential Therapy Followed by Autologous Stem-Cell Transplantation As First-Line Treatment in Poor-Risk, Aggressive Non-Hodgkinʼs Lymphoma: Comparative Analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40

Author

van Imhoff, Gustaaf W., van der Holt, Bronno, MacKenzie, Marius A., vanʼt Veer, Mars B., Wijermans, Pierre W., Ossenkoppele, Gerrit J., Schouten, Harry C., Sonneveld, Pieter, Steijaert, Monique M.C., Kluin, Philip M., Kluin-Nelemans, Hanneke C., and Verdonck, Leo F.

Published
2005
Full Text
View/download PDF

103. Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia:: A randomised phase II trial from HOVON, the Dutch–Belgian Haemato-Oncology Working Group for adults

Author

Daenen, Simon, van der Holt, Bronno, Verhoef, Gregor E.G, Löwenberg, Bob, Wijermans, Pierre W, Huijgens, Peter C, van Marwijk Kooy, Rien, Schouten, Harry C, Kramer, Mark H.H, Ferrant, Augustin, van den Berg, Eva, Steijaert, Monique M.C, Verdonck, Leo F, and Sonneveld, Pieter

Published
2004
Full Text
View/download PDF

104. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients : Center for International Blood and Marrow Transplant Research Report

Author

Kim, Haesook T., Ahn, Kwang Woo, Hu, Zhen-Huan, Davids, Matthew S., Volpe, Virginia O., Antin, Joseph H., Sorror, Mohamed L., Shadman, Mazyar, Press, Oliver, Pidala, Joseph, Hogan, William, Negrin, Robert, Devine, Steven, Uberti, Joseph, Agura, Edward, Nash, Richard, Mehta, Jayesh, McGuirk, Joseph, Forman, Stephen, Langston, Amelia, Giralt, Sergio A., Perales, Miguel-Angel, Battiwalla, Minoo, Hale, Gregory A., Gale, Robert Peter, Marks, David I., Hamadani, Mehdi, Ganguly, Sid, Bacher, Ulrike, Lazarus, Hillard, Reshef, Ran, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Cahn, Jean-Yves, Solh, Melhem, Kharfan-Dabaja, Mohamed A., Ghosh, Nilanjan, Saad, Ayman, Aljurf, Mahmoud, Schouten, Harry C., Hill, Brian T., Pawarode, Attaphol, Kindwall-Keller, Tamila, Saba, Nakhle, Copelan, Edward A., Nathan, Sunita, Beitinjaneh, Amer, Savani, Bipin N., Cerny, Jan, Grunwald, Michael R., Yared, Jean, Wirk, Baldeep M., Nishihori, Taiga, Chhabra, Saurabh, Olsson, Richard, Bashey, Asad, Gergis, Usama, Popat, Uday, Sobecks, Ronald, Alyea, Edwin, Saber, Wael, Brown, Jennifer R., Kim, Haesook T., Ahn, Kwang Woo, Hu, Zhen-Huan, Davids, Matthew S., Volpe, Virginia O., Antin, Joseph H., Sorror, Mohamed L., Shadman, Mazyar, Press, Oliver, Pidala, Joseph, Hogan, William, Negrin, Robert, Devine, Steven, Uberti, Joseph, Agura, Edward, Nash, Richard, Mehta, Jayesh, McGuirk, Joseph, Forman, Stephen, Langston, Amelia, Giralt, Sergio A., Perales, Miguel-Angel, Battiwalla, Minoo, Hale, Gregory A., Gale, Robert Peter, Marks, David I., Hamadani, Mehdi, Ganguly, Sid, Bacher, Ulrike, Lazarus, Hillard, Reshef, Ran, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Cahn, Jean-Yves, Solh, Melhem, Kharfan-Dabaja, Mohamed A., Ghosh, Nilanjan, Saad, Ayman, Aljurf, Mahmoud, Schouten, Harry C., Hill, Brian T., Pawarode, Attaphol, Kindwall-Keller, Tamila, Saba, Nakhle, Copelan, Edward A., Nathan, Sunita, Beitinjaneh, Amer, Savani, Bipin N., Cerny, Jan, Grunwald, Michael R., Yared, Jean, Wirk, Baldeep M., Nishihori, Taiga, Chhabra, Saurabh, Olsson, Richard, Bashey, Asad, Gergis, Usama, Popat, Uday, Sobecks, Ronald, Alyea, Edwin, Saber, Wael, and Brown, Jennifer R.

Abstract

Purpose: To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT). Experimental Design: We performed a retrospective analysis of outcomes of 606 patients with CLL who underwent RIC allogeneic HCT between 2008 and 2014 reported to the Center for International Blood and Marrow Transplant Research. Results: On the basis of multivariable models, disease status, comorbidity index, lymphocyte count, and white blood cell count at HCT were selected for the development of prognostic model. Using the prognostic score, we stratified patients into low-, intermediate-, high-, and very-high-risk [4-year progression-free survival (PFS) 58%, 42%, 33%, and 25%, respectively, P < 0.0001; 4-year overall survival (OS) 70%, 57%, 54%, and 38%, respectively, P < 0.0001]. We also evaluated karyotypic abnormalities together with del(17p) and found that del(17p) or >= 5 abnormalities showed inferior PFS. Using a multivariable model, we classified cytogenetic risk into low, intermediate, and high (P < 0.0001). When the prognostic score and cytogenetic risk were combined, patients with low prognostic score and low cytogenetic risk had prolonged PFS (61% at 4 years) and OS (75% at 4 years). Conclusions: In this large cohort of patients with previously treated CLL who underwent RIC HCT, we developed a robust prognostic scoring system of HCT outcomes and a novel cytogenetic-based risk stratification system. These prognostic models can be used for counseling patients, comparing data across studies, and providing a benchmark for future interventions. For future study, we will further validate these models for patients receiving targeted therapies prior to HCT.

Published
2019
Full Text
View/download PDF

105. Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation

Author

Norkin, Maxim, Shaw, Bronwen E, Brazauskas, Ruta, Tecca, Heather R, Leather, Helen L, Gea-Banacloche, Juan, T Kamble, Rammurti, DeFilipp, Zachariah, Jacobsohn, David A, Ringden, Olle, Inamoto, Yoshihiro, A Kasow, Kimberly, Buchbinder, David, Shaw, Peter, Hematti, Peiman, Schears, Raquel, Badawy, Sherif M, Lazarus, Hillard M, Bhatt, Neel, Horn, Biljana, Chhabra, Saurabh, M Page, Kristin, Hamilton, Betty, Hildebrandt, Gerhard C, Yared, Jean A, Agrawal, Vaibhav, M Beitinjaneh, Amer, Majhail, Navneet, Kindwall-Keller, Tamila, Olsson, Richard F., Schoemans, Helene, Gale, Robert Peter, Ganguly, Siddhartha, A Ahmed, Ibrahim, Schouten, Harry C, L Liesveld, Jane, Khera, Nandita, Steinberg, Amir, Shah, Ami J, Solh, Melhem, Marks, David I, Rybka, Witold, Aljurf, Mahmoud, Dietz, Andrew C, Gergis, Usama, George, Biju, Seo, Sachiko, Flowers, Mary E D, Battiwalla, Minoo, Savani, Bipin N, Riches, Marcie L, Wingard, John R, Norkin, Maxim, Shaw, Bronwen E, Brazauskas, Ruta, Tecca, Heather R, Leather, Helen L, Gea-Banacloche, Juan, T Kamble, Rammurti, DeFilipp, Zachariah, Jacobsohn, David A, Ringden, Olle, Inamoto, Yoshihiro, A Kasow, Kimberly, Buchbinder, David, Shaw, Peter, Hematti, Peiman, Schears, Raquel, Badawy, Sherif M, Lazarus, Hillard M, Bhatt, Neel, Horn, Biljana, Chhabra, Saurabh, M Page, Kristin, Hamilton, Betty, Hildebrandt, Gerhard C, Yared, Jean A, Agrawal, Vaibhav, M Beitinjaneh, Amer, Majhail, Navneet, Kindwall-Keller, Tamila, Olsson, Richard F., Schoemans, Helene, Gale, Robert Peter, Ganguly, Siddhartha, A Ahmed, Ibrahim, Schouten, Harry C, L Liesveld, Jane, Khera, Nandita, Steinberg, Amir, Shah, Ami J, Solh, Melhem, Marks, David I, Rybka, Witold, Aljurf, Mahmoud, Dietz, Andrew C, Gergis, Usama, George, Biju, Seo, Sachiko, Flowers, Mary E D, Battiwalla, Minoo, Savani, Bipin N, Riches, Marcie L, and Wingard, John R

Abstract

We analyzed late fatal infections (LFIs) in allogeneic stem cell transplantation (HCT) recipients reported to the Center for International Blood and Marrow Transplant Research. We analyzed the incidence, infection types, and risk factors contributing to LFI in 10,336 adult and 5088 pediatric subjects surviving for ≥2 years after first HCT without relapse. Among 2245 adult and 377 pediatric patients who died, infections were a primary or contributory cause of death in 687 (31%) and 110 (29%), respectively. At 12 years post-HCT, the cumulative incidence of LFIs was 6.4% (95% confidence interval [CI], 5.8% to 7.0%) in adults, compared with 1.8% (95% CI, 1.4% to 2.3%) in pediatric subjects; P < .001). In adults, the 2 most significant risks for developing LFI were increasing age (20 to 39, 40 to 54, and ≥55 years versus 18 to 19 years) with hazard ratios (HRs) of 3.12 (95% CI, 1.33 to 7.32), 3.86 (95% CI, 1.66 to 8.95), and 5.49 (95% CI, 2.32 to 12.99) and a history of chronic graft-versus-host disease GVHD (cGVHD) with ongoing immunosuppression at 2 years post-HCT compared with no history of GVHD with (HR, 3.87; 95% CI, 2.59 to 5.78). In pediatric subjects, the 3 most significant risks for developing LFI were a history of cGVHD with ongoing immunosuppression (HR, 9.49; 95% CI, 4.39 to 20.51) or without ongoing immunosuppression (HR, 2.7; 95% CI, 1.05 to 7.43) at 2 years post-HCT compared with no history of GVHD, diagnosis of inherited abnormalities of erythrocyte function compared with diagnosis of acute myelogenous leukemia (HR, 2.30; 95% CI, 1.19 to 4.42), and age >10 years (HR, 1.92; 95% CI, 1.15 to 3.2). This study emphasizes the importance of continued vigilance for late infections after HCT and institution of support strategies aimed at decreasing the risk of cGVHD.

Published
2019
Full Text
View/download PDF

106. Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis

Author

Robin, Marie, Chevret, Sylvie, Koster, Linda, Wolschke, Christine, Yakoub-Agha, Ibrahim, Bourhis, Jean Henri, Chevallier, Patrice, Cornelissen, Jan J., Remenyi, Peter, Maertens, Johan, Poire, Xavier, Craddock, Charles, Socie, Gerard, Itala-Remes, Maija, Schouten, Harry C., Marchand, Tony, Passweg, Jakob, Blaise, Didier, Damaj, Gandhi, Ozkurt, Zubeyde Nur, Zuckerman, Tsila, Cluzeau, Thomas, Labussiere-Wallet, Helene, Cammenga, Jörg, McLornan, Donal, Chalandon, Yves, Kroger, Nicolaus, Robin, Marie, Chevret, Sylvie, Koster, Linda, Wolschke, Christine, Yakoub-Agha, Ibrahim, Bourhis, Jean Henri, Chevallier, Patrice, Cornelissen, Jan J., Remenyi, Peter, Maertens, Johan, Poire, Xavier, Craddock, Charles, Socie, Gerard, Itala-Remes, Maija, Schouten, Harry C., Marchand, Tony, Passweg, Jakob, Blaise, Didier, Damaj, Gandhi, Ozkurt, Zubeyde Nur, Zuckerman, Tsila, Cluzeau, Thomas, Labussiere-Wallet, Helene, Cammenga, Jörg, McLornan, Donal, Chalandon, Yves, and Kroger, Nicolaus

Abstract

The use of antihuman T-lymphocyte immunoglobulin in the setting of transplantation from an HLA-matched related donor is still much debated. Acute and chronic graft-versus-host disease are the main causes of morbidity and mortality after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. The aim of this study was to evaluate the effect of antihuman T-lymphocyte immunoglobulin in a large cohort of patients with myelofibrosis (n= 287). The cumulative incidences of grade II-IV acute graft-versus-host disease among patients who were or were not given antihuman T-lymphocyte immunoglobulin were 26% and 41%, respectively. The corresponding incidences of chronic graft-versus-host disease were 52% and 55%, respectively. Non-adjusted overall survival, disease-free survival and non-relapse mortality rates were 55% versus 53%, 49% versus 45%, and 32% versus 31%, respectively, among the patients who were or were not given antihuman T-lymphocyte immunoglobulin. An adjusted model confirmed that the risk of acute graft-versus-host disease was lower following antihuman T-lymphocyte immunoglobulin (hazard ratio, 0.54; P= 0.010) while it did not decrease the risk of chronic graft-versus-host disease. The hazard ratios for overall survival and non-relapse mortality were 0.66 and 0.64, with P-values of 0.05 and 0.09, respectively. Antihuman T-lymphocyte immunoglobulin did not influence disease-free survival, graft-versus-host disease, relapse-free survival or relapse risk. In conclusion, in the setting of matched related transplantation in myelofibrosis patients, this study demonstrates that antihuman T-lymphocyte immunoglobulin decreases the risk of acute graft-versushost disease without increasing the risk of relapse.

Published
2019
Full Text
View/download PDF

107. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24) : a randomised, open-label, phase 3 intergroup study

Author

Bromberg, Jacoline E.C., Issa, Samar, Bakunina, Katerina, Minnema, Monique C., Seute, Tatjana, Durian, Marc, Cull, Gavin, Schouten, Harry C., Stevens, Wendy B.C., Zijlstra, Josee M., Baars, Joke W., Nijland, Marcel, Mason, Kylie D., Beeker, Aart, van den Bent, Martin J., Beijert, Max, Gonzales, Michael, de Jong, Daphne, Doorduijn, Jeanette K., Bromberg, Jacoline E.C., Issa, Samar, Bakunina, Katerina, Minnema, Monique C., Seute, Tatjana, Durian, Marc, Cull, Gavin, Schouten, Harry C., Stevens, Wendy B.C., Zijlstra, Josee M., Baars, Joke W., Nijland, Marcel, Mason, Kylie D., Beeker, Aart, van den Bent, Martin J., Beijert, Max, Gonzales, Michael, de Jong, Daphne, and Doorduijn, Jeanette K.

Published
2019

108. Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment

Author

Leader, Avi, Leader, Avi, Ten Cate, Vincent, Ten Cate-Hoek, Anna J., Spectre, Galia, Beckers, Erik A. M., Raanani, Pia, Giaccherini, Cinzia, Pereg, David, Schouten, Harry C., Falanga, Anna, Ten Cate, Hugo, Leader, Avi, Leader, Avi, Ten Cate, Vincent, Ten Cate-Hoek, Anna J., Spectre, Galia, Beckers, Erik A. M., Raanani, Pia, Giaccherini, Cinzia, Pereg, David, Schouten, Harry C., Falanga, Anna, and Ten Cate, Hugo

Abstract

Data on anti-platelet therapy (APT) for prevention of atherothrombotic events in thrombocytopaenic cancer patients is lacking. We aimed to identify patient and physician characteristics associated with APT management in thrombocytopaenic patients with haematological malignancy. A clinical vignette-based experiment was designed. Eleven haematologists were interviewed, identifying five variable categories. Next, 18 hypothetical vignettes were generated. Each physician received three vignettes and chose to: hold all APT; continue APT without platelet transfusion support; or continue APT with platelet transfusion support. The survey was distributed to haematologists and thrombosis specialists in three countries. Multivariate cluster robust Poisson regression models were used to calculate relative risks (RRs) of using one management option (over the other) for each variable in comparison to a reference variable. A total of 145 physicians answered 434 cases. Clinicians were more likely to hold APT in case of 20,000/mu L platelets (vs. 40,000/mu L; RR for continuing: 0.82 [95% confidence interval: 0.75-0.91]), recent major gastrointestinal bleeding (vs. none; RR 0.81 [0.72-0.92]) and when the physician worked at a university-affiliated community hospital (vs. non-academic community hospital; RR 0.84 [0.72-0.98]). Clinicians were more likely to continue APT in ST elevation myocardial infarction with dual APT (vs. unstable angina with single APT; RR 1.31 [1.18-1.45]) and when there were institutional protocols guiding management (vs. none; RR 1.15 [1.03-1.27]). When APT was continued, increased platelet transfusion targets were used in 34%. In summary, the decision process is complex and affected by multiple patient and physician characteristics. Platelet transfusions were frequently chosen to support APT, although no evidence supports this practice.

Published
2019

109. Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature

Author

Cancer, Infection & Immunity, MS Hematologie, Regenerative Medicine and Stem Cells, Slot, Stefanie, Raymakers, Reinier A P, Schaap, Nicolaas, Span, Lambert F R, Koene, Harry R, Kersting, Sabina, Te Boekhorst, Peter A W, Westerman, Matthijs, Schouten, Harry C, Zweegman, Sonja, Cancer, Infection & Immunity, MS Hematologie, Regenerative Medicine and Stem Cells, Slot, Stefanie, Raymakers, Reinier A P, Schaap, Nicolaas, Span, Lambert F R, Koene, Harry R, Kersting, Sabina, Te Boekhorst, Peter A W, Westerman, Matthijs, Schouten, Harry C, and Zweegman, Sonja

Published
2019

110. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Author

Divisie Beeld & Oncologie, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, UMC Utrecht, Neurologie, ZL Neuro-Oncologie Medisch, Bromberg, Jacoline E.C., Issa, Samar, Bakunina, Katerina, Minnema, Monique C., Seute, Tatjana, Durian, Marc, Cull, Gavin, Schouten, Harry C., Stevens, Wendy B.C., Zijlstra, Josee M., Baars, Joke W., Nijland, Marcel, Mason, Kylie D., Beeker, Aart, van den Bent, Martin J., Beijert, Max, Gonzales, Michael, de Jong, Daphne, Doorduijn, Jeanette K., Divisie Beeld & Oncologie, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, UMC Utrecht, Neurologie, ZL Neuro-Oncologie Medisch, Bromberg, Jacoline E.C., Issa, Samar, Bakunina, Katerina, Minnema, Monique C., Seute, Tatjana, Durian, Marc, Cull, Gavin, Schouten, Harry C., Stevens, Wendy B.C., Zijlstra, Josee M., Baars, Joke W., Nijland, Marcel, Mason, Kylie D., Beeker, Aart, van den Bent, Martin J., Beijert, Max, Gonzales, Michael, de Jong, Daphne, and Doorduijn, Jeanette K.

Published
2019

111. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma

Author

Verdonck, Leo F., Putten, Wim L.J. van, Hagenbeek, Anton, Schouten, Harry C., Sonneveld, Pieter, Imhoff, Gustaaf W. van, Kluin-Nelemans, Hanneke C., Raemaekers, John M.M., Oers, Rien H.J. van, Haak, Hans L., Schots, Rik, Dekker, Adriaan W., Gast, Gijsbert C. de, and Lowenberg, Bob

Subjects
Non-Hodgkin's lymphomas -- Care and treatment, Autografts -- Evaluation, Bone marrow -- Transplantation, Cyclophosphamide -- Evaluation, Doxorubicin -- Evaluation, Vincristine -- Evaluation, Prednisone -- Evaluation
Abstract

A combination of high-dose chemotherapy, radiation and autologous bone marrow transplantation does not appear to be more effective than chemotherapy alone in patients with non-Hodgkin's lymphoma who respond slowly to initial chemotherapy. Of 286 non-Hodgkin's patients treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), 106 did not respond completely. Fifty-four of these patients were randomized into two groups: 28 received five more courses of CHOP chemotherapy and 26 donated bone marrow which was given back to them after a course of chemotherapy and radiation. After four years, disease-free survival rates and overall survival rates were similar in both groups. Patients who responded slowly to the initial chemotherapy regimen and had no bone marrow disease survived as long as those who responded rapidly, regardless of which treatment they received.

Published
1995

114. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma

Author

van Besien, Koen, Loberiza, Fausto R., Jr, Bajorunaite, Ruta, Armitage, James O., Bashey, Asad, Burns, Linda J., Freytes, Cesar O., Gibson, John, Horowitz, Mary M., Inwards, David J., Marks, David I., Martino, Rodrigo, Maziarz, Richard T., Molina, Arturo, Pavlovsky, Santiago, Pecora, Andrew L., Schouten, Harry C., Shea, Thomas C., Lazarus, Hillard M., Rizzo, J. Douglas, and Vose, Julie M.

Published
2003
Full Text
View/download PDF

115. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

Author

Segeren, Christine M., Sonneveld, Pieter, van der Holt, Bronno, Vellenga, Edo, Croockewit, Alexandra J., Verhoef, Gregor E.G., Cornelissen, Jan J., Schaafsma, Martijn R., van Oers, Marinus H.J., Wijermans, Pierre W., Fibbe, Wim E., Wittebol, Shulamit, Schouten, Harry C., Kooy, Marinus van Marwijk, Biesma, Douwe H., Baars, Joke W., Slater, Rosalyn, Steijaert, Monique M.C., Buijt, Ivon, and Lokhorst, Henk M.

Published
2003
Full Text
View/download PDF

116. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

Author

Kim, Haesook T., primary, Ahn, Kwang Woo, additional, Hu, Zhen-Huan, additional, Davids, Matthew S., additional, Volpe, Virginia O., additional, Antin, Joseph H., additional, Sorror, Mohamed L., additional, Shadman, Mazyar, additional, Press, Oliver, additional, Pidala, Joseph, additional, Hogan, William, additional, Negrin, Robert, additional, Devine, Steven, additional, Uberti, Joseph, additional, Agura, Edward, additional, Nash, Richard, additional, Mehta, Jayesh, additional, McGuirk, Joseph, additional, Forman, Stephen, additional, Langston, Amelia, additional, Giralt, Sergio A., additional, Perales, Miguel-Angel, additional, Battiwalla, Minoo, additional, Hale, Gregory A., additional, Gale, Robert Peter, additional, Marks, David I., additional, Hamadani, Mehdi, additional, Ganguly, Sid, additional, Bacher, Ulrike, additional, Lazarus, Hillard, additional, Reshef, Ran, additional, Hildebrandt, Gerhard C., additional, Inamoto, Yoshihiro, additional, Cahn, Jean-Yves, additional, Solh, Melhem, additional, Kharfan-Dabaja, Mohamed A., additional, Ghosh, Nilanjan, additional, Saad, Ayman, additional, Aljurf, Mahmoud, additional, Schouten, Harry C., additional, Hill, Brian T., additional, Pawarode, Attaphol, additional, Kindwall-Keller, Tamila, additional, Saba, Nakhle, additional, Copelan, Edward A., additional, Nathan, Sunita, additional, Beitinjaneh, Amer, additional, Savani, Bipin N., additional, Cerny, Jan, additional, Grunwald, Michael R., additional, Yared, Jean, additional, Wirk, Baldeep M., additional, Nishihori, Taiga, additional, Chhabra, Saurabh, additional, Olsson, Richard F., additional, Bashey, Asad, additional, Gergis, Usama, additional, Popat, Uday, additional, Sobecks, Ronald, additional, Alyea, Edwin, additional, Saber, Wael, additional, and Brown, Jennifer R., additional

Published
2019
Full Text
View/download PDF

117. Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation

Author

Dietrich, Sascha, primary, Dreger, Peter, additional, Hermine, Olivier, additional, Kyriakou, Chara, additional, Montoto, Silvia, additional, Robinson, Steve, additional, Schmitz, Norbert, additional, Schouten, Harry C, additional, Sureda, Anna, additional, and Tanase, Alina, additional

Published
2019
Full Text
View/download PDF

118. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.

Author

Harrison, Claire N., primary, Schaap, Nicolaas, additional, Vannucchi, Alessandro M, additional, Kiladjian, Jean-Jacques, additional, Jourdan, Eric, additional, Silver, Richard T., additional, Schouten, Harry C., additional, Passamonti, Francesco, additional, Zweegman, Sonja, additional, Talpaz, Moshe, additional, Verstovsek, Srdan, additional, Gerike, Torsten, additional, Rose, Shelonitda, additional, Li, Mingyu, additional, Brownstein, Carrie, additional, and Mesa, Ruben A., additional

Published
2019
Full Text
View/download PDF

119. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation

Author

Brunstein, Claudio G., primary, Pasquini, Marcelo C., additional, Kim, Soyoung, additional, Fei, Mingwei, additional, Adekola, Kehinde, additional, Ahmed, Ibrahim, additional, Aljurf, Mahmoud, additional, Agrawal, Vaibhav, additional, Auletta, Jeffrey J., additional, Battiwalla, Minoo, additional, Bejanyan, Nelli, additional, Bubalo, Joseph, additional, Cerny, Jan, additional, Chee, Lynette, additional, Ciurea, Stefan O., additional, Freytes, Cesar, additional, Gadalla, Shahinaz M., additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Hashmi, Shahrukh K., additional, Hematti, Peiman, additional, Hildebrandt, Gerhard, additional, Holmberg, Leona A., additional, Lahoud, Oscar B., additional, Landau, Heather, additional, Lazarus, Hillard M., additional, de Lima, Marcos, additional, Mathews, Vikram, additional, Maziarz, Richard, additional, Nishihori, Taiga, additional, Norkin, Maxim, additional, Olsson, Richard, additional, Reshef, Ran, additional, Rotz, Seth, additional, Savani, Bipin, additional, Schouten, Harry C., additional, Seo, Sachiko, additional, Wirk, Baldeep M., additional, Yared, Jean, additional, Mineishi, Shin, additional, Rogosheske, John, additional, and Perales, Miguel-Angel, additional

Published
2019
Full Text
View/download PDF

120. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Author

Bromberg, Jacoline E C, primary, Issa, Samar, additional, Bakunina, Katerina, additional, Minnema, Monique C, additional, Seute, Tatjana, additional, Durian, Marc, additional, Cull, Gavin, additional, Schouten, Harry C, additional, Stevens, Wendy B C, additional, Zijlstra, Josee M, additional, Baars, Joke W, additional, Nijland, Marcel, additional, Mason, Kylie D, additional, Beeker, Aart, additional, van den Bent, Martin J, additional, Beijert, Max, additional, Gonzales, Michael, additional, de Jong, Daphne, additional, and Doorduijn, Jeanette K, additional

Published
2019
Full Text
View/download PDF

121. Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation

Author

Norkin, Maxim, primary, Shaw, Bronwen E., additional, Brazauskas, Ruta, additional, Tecca, Heather R., additional, Leather, Helen L., additional, Gea-Banacloche, Juan, additional, T. Kamble, Rammurti, additional, DeFilipp, Zachariah, additional, Jacobsohn, David A., additional, Ringden, Olle, additional, Inamoto, Yoshihiro, additional, A. Kasow, Kimberly, additional, Buchbinder, David, additional, Shaw, Peter, additional, Hematti, Peiman, additional, Schears, Raquel, additional, Badawy, Sherif M., additional, Lazarus, Hillard M., additional, Bhatt, Neel, additional, Horn, Biljana, additional, Chhabra, Saurabh, additional, M. Page, Kristin, additional, Hamilton, Betty, additional, Hildebrandt, Gerhard C., additional, Yared, Jean A., additional, Agrawal, Vaibhav, additional, M. Beitinjaneh, Amer, additional, Majhail, Navneet, additional, Kindwall-Keller, Tamila, additional, Olsson, Richard F., additional, Schoemans, Helene, additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, A. Ahmed, Ibrahim, additional, Schouten, Harry C., additional, L. Liesveld, Jane, additional, Khera, Nandita, additional, Steinberg, Amir, additional, Shah, Ami J., additional, Solh, Melhem, additional, Marks, David I., additional, Rybka, Witold, additional, Aljurf, Mahmoud, additional, Dietz, Andrew C., additional, Gergis, Usama, additional, George, Biju, additional, Seo, Sachiko, additional, Flowers, Mary E.D., additional, Battiwalla, Minoo, additional, Savani, Bipin N., additional, Riches, Marcie L., additional, and Wingard, John R., additional

Published
2019
Full Text
View/download PDF

122. Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis

Author

Robin, Marie, primary, Chevret, Sylvie, additional, Koster, Linda, additional, Wolschke, Christine, additional, Yakoub-Agha, Ibrahim, additional, Bourhis, Jean Henri, additional, Chevallier, Patrice, additional, Cornelissen, Jan J., additional, Reményi, Péter, additional, Maertens, Johan, additional, Poiré, Xavier, additional, Craddock, Charles, additional, Socié, Gérard, additional, Itälä-Remes, Maija, additional, Schouten, Harry C., additional, Marchand, Tony, additional, Passweg, Jakob, additional, Blaise, Didier, additional, Damaj, Gandhi, additional, Ozkurt, Zubeyde Nur, additional, Zuckerman, Tsila, additional, Cluzeau, Thomas, additional, Labussière-Wallet, Hélène, additional, Cammenga, Jörg, additional, McLornan, Donal, additional, Chalandon, Yves, additional, and Kröger, Nicolaus, additional

Published
2019
Full Text
View/download PDF

123. Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation

Author

Chhabra, Saurabh, primary, Liu, Ying, additional, Hemmer, Michael T., additional, Costa, Luciano, additional, Pidala, Joseph A., additional, Couriel, Daniel R., additional, Alousi, Amin M., additional, Majhail, Navneet S., additional, Stuart, Robert K., additional, Kim, Dennis, additional, Ringden, Olle, additional, Urbano-Ispizua, Alvaro, additional, Saad, Ayman, additional, Savani, Bipin N., additional, Cooper, Brenda, additional, Marks, David I., additional, Socie, Gerard, additional, Schouten, Harry C., additional, Schoemans, Helene, additional, Abdel-Azim, Hisham, additional, Yared, Jean, additional, Cahn, Jean-Yves, additional, Wagner, John, additional, Antin, Joseph H., additional, Verdonck, Leo F., additional, Lehmann, Leslie, additional, Aljurf, Mahmoud D., additional, MacMillan, Margaret L., additional, Litzow, Mark R., additional, Solh, Melhem M., additional, Qayed, Muna, additional, Hematti, Peiman, additional, Kamble, Rammurti T., additional, Vij, Ravi, additional, Hayashi, Robert J., additional, Gale, Robert P., additional, Martino, Rodrigo, additional, Seo, Sachiko, additional, Hashmi, Shahrukh K., additional, Nishihori, Taiga, additional, Teshima, Takanori, additional, Gergis, Usama, additional, Inamoto, Yoshihiro, additional, Spellman, Stephen R., additional, Arora, Mukta, additional, and Hamilton, Betty K., additional

Published
2019
Full Text
View/download PDF

124. Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission

Author

Poiré, Xavier, primary, Labopin, Myriam, additional, Polge, Emmanuelle, additional, Blaise, Didier, additional, Chevallier, Patrice, additional, Maertens, Johan, additional, Deconinck, Eric, additional, Forcade, Edouard, additional, Rambaldi, Alessandro, additional, Baerlocher, Gabriela M., additional, Zuckerman, Tsila, additional, Volin, Liisa, additional, Schouten, Harry C., additional, Ifrah, Norbert, additional, Mohty, Mohamad, additional, Esteve, Jordi, additional, and Nagler, Arnon, additional

Published
2018
Full Text
View/download PDF

125. Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party

Author

Onida, Francesco, primary, Sbianchi, Giulia, additional, Koster, Linda, additional, Iacobelli, Simona, additional, Dreger, Peter, additional, Bornhäuser, Martin, additional, Kröger, Nicolaus, additional, Sierra, Jorge, additional, Socié, Gérard, additional, Cornelissen, Jan J, additional, Poire, Xavier, additional, Faber, Edgar, additional, Bourhis, Jean-Henri, additional, Finke, Jürgen, additional, Passweg, Jakob R., additional, Salmenniemi, Urpu, additional, Schouten, Harry C., additional, Beguin, Yves, additional, Martin, Sonja, additional, Deconinck, Eric, additional, Ganser, Arnold, additional, Zver, Samo, additional, Lioure, Bruno, additional, Russell, Nigel H., additional, Robin, Marie, additional, and Yakoub-Agha, Ibrahim, additional

Published
2018
Full Text
View/download PDF

126. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia

Author

Chhabra, Saurabh, primary, Ahn, Kwang Woo, additional, Hu, Zhen-Huan, additional, Jain, Sandeep, additional, Assal, Amer, additional, Cerny, Jan, additional, Copelan, Edward A., additional, Daly, Andrew, additional, DeFilipp, Zachariah, additional, Gadalla, Shahinaz M., additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Hamilton, Betty K., additional, Hildebrandt, Gerhard Carl, additional, Hsu, Jack W., additional, Inamoto, Yoshihiro, additional, Kanate, Abraham S., additional, Khoury, H. Jean, additional, Lazarus, Hillard M., additional, Litzow, Mark R., additional, Nathan, Sunita, additional, Olsson, Richard F., additional, Pawarode, Attaphol, additional, Ringden, Olle, additional, Rowe, Jacob M., additional, Saad, Ayman, additional, Savani, Bipin N., additional, Schouten, Harry C., additional, Seo, Sachiko, additional, Shah, Nirav N., additional, Solh, Melhem, additional, Stuart, Robert K., additional, Ustun, Celalettin, additional, Woolfrey, Ann E., additional, Yared, Jean A., additional, Alyea, Edwin P., additional, Kalaycio, Matt E., additional, Popat, Uday, additional, Sobecks, Ronald M., additional, and Saber, Wael, additional

Published
2018
Full Text
View/download PDF

128. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor–mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes

Author

Guardiola, Philippe, Runde, Volker, Bacigalupo, Andrea, Ruutu, Tapani, Locatelli, Franco, Boogaerts, Marc A., Pagliuca, Antonio, Cornelissen, Jan J., Schouten, Harry C., Carreras, Enric, Finke, Jürgen, van Biezen, Anja, Brand, Ronald, Niederwieser, Dietger, Gluckman, Eliane, and de Witte, Theo M.

Published
2002
Full Text
View/download PDF

132. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia

Author

Chhabra, Saurabh, Ahn, Kwang Woo, Hu, Zhen-Huan, Jain, Sandeep, Assal, Amer, Cerny, Jan, Copelan, Edward A., Daly, Andrew, DeFilipp, Zachariah, Gadalla, Shahinaz M., Gale, Robert Peter, Ganguly, Siddhartha, Hamilton, Betty K., Hildebrandt, Gerhard Carl, Hsu, Jack W., Inamoto, Yoshihiro, Kanate, Abraham S., Khoury, H. Jean, Lazarus, Hillard M., Litzow, Mark R., Nathan, Sunita, Olsson, Richard, Pawarode, Attaphol, Ringden, Olle, Rowe, Jacob M., Saad, Ayman, Savani, Bipin N., Schouten, Harry C., Seo, Sachiko, Shah, Nirav N., Solh, Melhem, Stuart, Robert K., Ustun, Celalettin, Woolfrey, Ann E., Yared, Jean A., Alyea, Edwin P., Kalaycio, Matt E., Popat, Uday, Sobecks, Ronald M., Saber, Wael, Chhabra, Saurabh, Ahn, Kwang Woo, Hu, Zhen-Huan, Jain, Sandeep, Assal, Amer, Cerny, Jan, Copelan, Edward A., Daly, Andrew, DeFilipp, Zachariah, Gadalla, Shahinaz M., Gale, Robert Peter, Ganguly, Siddhartha, Hamilton, Betty K., Hildebrandt, Gerhard Carl, Hsu, Jack W., Inamoto, Yoshihiro, Kanate, Abraham S., Khoury, H. Jean, Lazarus, Hillard M., Litzow, Mark R., Nathan, Sunita, Olsson, Richard, Pawarode, Attaphol, Ringden, Olle, Rowe, Jacob M., Saad, Ayman, Savani, Bipin N., Schouten, Harry C., Seo, Sachiko, Shah, Nirav N., Solh, Melhem, Stuart, Robert K., Ustun, Celalettin, Woolfrey, Ann E., Yared, Jean A., Alyea, Edwin P., Kalaycio, Matt E., Popat, Uday, Sobecks, Ronald M., and Saber, Wael

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment of chronic myeloid leukemia (CML). Optimal conditioning intensity for allo-HCT for CML in the era of tyrosine kinase inhibitors (TKIs) is unknown. Using the Center for International Blood and Marrow Transplant Research database, we sought to determine whether reduced-intensity/nonmyeloablative conditioning (RIC) allo-HCT and myeloablative conditioning (MAC) result in similar outcomes in CML patients. We evaluated 1395 CML allo-HCT recipients between the ages of 18 and 60 years. The disease status at transplant was divided into the following categories: chronic phase 1, chronic phase 2 or greater, and accelerated phase. Patients in blast phase at transplant and alternative donor transplants were excluded. The primary outcome was overall survival (OS) after allo-HCT. MAC (n = 1204) and RIC allo-HCT recipients (n = 191) from 2007 to 2014 were included. Patient, disease, and transplantation characteristics were similar, with a few exceptions. Multivariable analysis showed no significant difference in OS between MAC and RIC groups. In addition, leukemia-free survival and nonrelapse mortality did not differ significantly between the 2 groups. Compared with MAC, the RIC group had a higher risk of early relapse after allo-HCT (hazard ratio [HR], 1.85; P = .001). The cumulative incidence of chronic graft-versus-host disease (cGVHD) was lower with RIC than with MAC (HR, 0.77; P = .02). RIC provides similar survival and lower cGVHD compared with MAC and therefore may be a reasonable alternative to MAC for CML patients in the TKI era.

Published
2018
Full Text
View/download PDF

133. Correspondence: Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation

Author

Turcotte, Lucie M., Wang, Tao, Hemmer, Michael T., Spellman, Stephen R., Arora, Mukta, Couriel, Daniel, Alousi, Amin, Pidala, Joseph, Abdel-Azim, Hisham, Ahmed, Ibrahim, Beitinjaneh, Amer, Buchbinder, David, Byrne, Michael, Callander, Natalie, Chao, Nelson, Choi, Sung Wong, DeFilipp, Zachariah, Gadalla, Shahinaz M., Gale, Robert Peter, Gergis, Usama, Hashmi, Shahrukh, Hematti, Peiman, Holmberg, Leona, Inamoto, Yoshihiro, Kamble, Rammurti T., Lehmann, Leslie, MacMillan, Margaret A., McIver, Zachariah, Nishihori, Taiga, Norkin, Maxim, O'Brien, Tracey, Olsson, Richard, Reshef, Ran, Saad, Ayman, Savani, Bipin N., Schouten, Harry C., Seo, Sachiko, Solh, Melhem, Verdonck, Leo, Vij, Ravi, Wirk, Baldeep, Yared, Jean, Horowitz, Mary M., Knight, Jennifer M., Verneris, Michael R., Turcotte, Lucie M., Wang, Tao, Hemmer, Michael T., Spellman, Stephen R., Arora, Mukta, Couriel, Daniel, Alousi, Amin, Pidala, Joseph, Abdel-Azim, Hisham, Ahmed, Ibrahim, Beitinjaneh, Amer, Buchbinder, David, Byrne, Michael, Callander, Natalie, Chao, Nelson, Choi, Sung Wong, DeFilipp, Zachariah, Gadalla, Shahinaz M., Gale, Robert Peter, Gergis, Usama, Hashmi, Shahrukh, Hematti, Peiman, Holmberg, Leona, Inamoto, Yoshihiro, Kamble, Rammurti T., Lehmann, Leslie, MacMillan, Margaret A., McIver, Zachariah, Nishihori, Taiga, Norkin, Maxim, O'Brien, Tracey, Olsson, Richard, Reshef, Ran, Saad, Ayman, Savani, Bipin N., Schouten, Harry C., Seo, Sachiko, Solh, Melhem, Verdonck, Leo, Vij, Ravi, Wirk, Baldeep, Yared, Jean, Horowitz, Mary M., Knight, Jennifer M., and Verneris, Michael R.

Published
2018
Full Text
View/download PDF

134. Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen

Author

Baron, Frédéric, Labopin, Myriam, Ruggeri, Annalisa, Cornelissen, Jan J, Meijer, Ellen, Sengeloev, Henrik, Niederwieser, Dietger, De Groot, Marco R, Schouten, Harry C, Milpied, Noel, Blaise, Didier, Savani, Bipin N, Gluckman, Eliane, Mohty, Mohamad, Nagler, Arnon, Baron, Frédéric, Labopin, Myriam, Ruggeri, Annalisa, Cornelissen, Jan J, Meijer, Ellen, Sengeloev, Henrik, Niederwieser, Dietger, De Groot, Marco R, Schouten, Harry C, Milpied, Noel, Blaise, Didier, Savani, Bipin N, Gluckman, Eliane, Mohty, Mohamad, and Nagler, Arnon

Abstract

Purpose: We assessed the impact of donor type in acute myeloid leukemia (AML) patients transplanted with 2 Gy total body irradiation (TBI)-based nonmyeloablative conditioning regimen.Patients and Methods: Data from 1,715 adult patients, with AML in CR1 or CR2 were included in this retrospective survey.Results: Donors consisted either of HLA-matched sibling donors (MSD, n = 701), 10/10 HLA-matched unrelated donors (MUD, n = 611), HLA-haploidentical donors (haplo, n = 112) or single or double umbilical cord bloods (CBT, n = 291). Chronic graft-versus-host disease (GVHD) was less frequent in CBT (28%) and in haplo (30%) patients than in MSD (50%) and MUD (51%) recipients (P < 0.001). Two-year incidence of relapse was 32%, 30%, 34%, and 34% in MSD, MUD, CBT and haplo patients, respectively (P = 0.7). Two-year overall (OS) and GVHD-free relapse-free survival (GRFS) were 59% and 29% in MSD patients, 56% and 39% in CBT recipients, 53% and 23% in MUD recipients, and 43% and 37% in haplo patients, respectively. In multivariate analyses, MUD patients had lower GRFS than MSD patients beyond day 100 (HR 1.3, P = 0.001) while CBT was associated with a better GRFS than MSD beyond day 100 (HR 0.6, P = 0.002).Conclusions: In this large cohort of AML patients transplanted following low-dose TBI-based conditioning, the relapse incidence was not affected by donor type suggesting that the intensity of GVL effects might be comparable with these four transplant approaches. Furthermore, CBT was associated with better GRFS beyond day 100 than MSD while the opposite was observed for MUD. Clin Cancer Res; 24(12); 2794-803. ©2018 AACR.

Published
2018

135. Improved survival after acute graft

Author

Socie, Gerard, Schultz, Kirk R., Battiwalla, Minoo, Dandoy, Christopher, Lehmann, Leslie, Arora, Mukta, Gergis, Usama, Jamani, Kareem, Pidala, Joseph, Hashmi, Shahrukh, Kamble, Rammurti T., Hayashi, Robert J., Cutler, Corey, Savani, Bipin, Vij, Ravi, Spellman, Stephen, Juckett, Mark, Hemmer, Michael T., Wood, William A., Cairo, Mitchell, Solh, Melham, Hematti, Peiman, Martino, Rodrigo, Litzow, Mark, Aljurf, Mahmoud, Schoemans, Helene, Gale, Robert Peter, Antin, Joseph H., Chen, Yi-Bin, Kharfan-Dabaja, Mohamed, Wirk, Baldeep M., Cahn, Jean-Yves, Wang, Tao, Schouten, Harry C., Couriel, Daniel, Majhail, Navneet, Yu, Lolie, Qayed, Muna, Storek, Jan, Nishihori, Taiga, Miller, Alan, Khoury, Hanna J., Alousi, Amin, Carabasi, Matthew, Verdonck, Leo, and Jagasia, Madan

Abstract

A cute graft- versus -host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft- versus -host disease. We examined outcome following diagnosis of grade II-IV acute graft- versus -host disease according to time period, and explored effects according to original graft- versus -host disease prophylaxis regimen and maximum overall grade of acute graft- versus -host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft- versus -host disease (n=497 for 1999-2001, n=962 for 2002-2005, n=1,446 for 2006-2010). The median (range) follow-up was 144 (4-174), 97 (4-147) and 60 (8-99) months for 1999-2001, 2002-2005, and 2006-2010, respectively. Among the cohort with grade II-IV acute graft- versus -host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999-2001, 2002-2005, and 2006-2012, respectively ( P

Published
2017
Full Text
View/download PDF

136. In the Era of Chemoimmunotherapy, Relapse Post Autologous Stem Cell Transplantation for Follicular Lymphoma Is Associated with Prolonged Overall Survival. an Analysis By the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Author

Robinson, Stephen, Finel, Herve, Boumendil, Ariane, Tilly, Herve, Gilles Salles, Corradini, Paolo, Cairoli, Roberto, Pytlik, Robert, Schouten, Harry C., Lewerin, Catharina, Thieblemont, Catherine, Metzner, Bernd, Rambaldi, Alessandro, Ringhoffer, Mark, Lown, Robert, Rossi, Giuseppe, Bittenbring, Jorg Thomas, Bloor, Adrian, Illes, Arpad, Feugier, Pierre, Turlure, Pascal, Mufti, Ghulam, Heinicke, Thomas, Peggs, Karl, Poire, Xavier, Dreger, Peter, Montoto, Silvia, Robinson, S, Finel, H, Boumendil, A, Tilly, H, Salles, G, Corradini, P, Cairoli, R, Pytlik, R, Schouten, H, Leweri, N, Thieblemont, C, Metzner, B, Rambaldi, A, Ringhoffer, M, Lown, R, Rossi, G, Bittenbring, J, Bloor, A, Illes, A, Feugier, P, Turlure, P, Mufti, G, Heinicke, T, Peggs, K, Poire, X, Dreger, P, and Montoto, S

Subjects
Hematology
Published
2017

137. Rituximab‐PECC induction followed by 90Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.

Author

Lugtenburg, Pieternella J., Zijlstra, Josee M., Doorduijn, Jeanette K., Böhmer, Lara H., Hoogendoorn, Mels, Berenschot, Henriette W., Beeker, Aart, van der Burg‐de Graauw, Nicole C., Schouten, Harry C., Bilgin, Yavuz M., Kersten, Marie‐Jose, Koene, Harry R., Herbers, Alexandra H. E., de Jong, Daphne, Hijmering, Nathalie, Lam, King H., Chiţu, Dana, Brouwer, Rolf E., and van Imhoff, Gustaaf W.

Subjects
STEM cell transplantation
Abstract

Summary: Patients with relapsed/refractory diffuse large B‐cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R‐PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles in 62 patients, followed by radio‐immunotherapy consolidation with 90Y‐ibritumomab tiuxetan in responsive patients. Primary endpoints were failure‐free survival (FFS) and incidence of grade ≥3 adverse events from start of 90Y‐ibritumomab tiuxetan. The overall response rate after R‐PECC was 50%. Twenty‐nine of 31 responsive patients proceeded to 90Y‐ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after 90Y‐ibritumomab tiuxetan. One‐year FFS and overall survival (OS) from start of 90Y‐ibritumomab tiuxetan was 52% (95% confidence interval [CI], 33–68%) and 62% (95% CI, 42–77%), respectively. One‐year FFS and OS from start of R‐PECC was 28% (95% CI, 17–39%) and 49% (95% CI, 36–61%), respectively. Toxicities of R‐PECC and 90Y‐ibritumomab tiuxetan were mainly haematological. In conclusion, for relapsed DLBCL patients the largely oral R‐PECC regimen achieves promising response rates, combined with an acceptable safety profile. Consolidation with 90Y‐ibritumomab tiuxetan resulted in long‐term response durations in approximately one third of the patients that received it. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

138. Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen

Author

Baron, Frédéric, primary, Labopin, Myriam, additional, Ruggeri, Annalisa, additional, Cornelissen, Jan J., additional, Meijer, Ellen, additional, Sengeloev, Henrik, additional, Niederwieser, Dietger, additional, De Groot, Marco R., additional, Schouten, Harry C., additional, Milpied, Noel, additional, Blaise, Didier, additional, Savani, Bipin N., additional, Gluckman, Eliane, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2018
Full Text
View/download PDF

139. Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants

Author

Kumar, Anita J., primary, Kim, Soyoung, additional, Hemmer, Michael T., additional, Arora, Mukta, additional, Spellman, Stephen R., additional, Pidala, Joseph A., additional, Couriel, Daniel R., additional, Alousi, Amin M., additional, Aljurf, Mahmoud D., additional, Cahn, Jean-Yves, additional, Cairo, Mitchell S., additional, Cutler, Corey S., additional, Farhan, Shatha, additional, Gergis, Usama, additional, Hale, Gregory A., additional, Hashmi, Shahrukh K., additional, Inamoto, Yoshihiro, additional, Kamble, Rammurti T., additional, Kharfan-Dabaja, Mohamed A., additional, MacMillan, Margaret L., additional, Marks, David I., additional, Nakasone, Hideki, additional, Norkin, Maxim, additional, Qayed, Muna, additional, Ringden, Olle, additional, Schouten, Harry C., additional, Schultz, Kirk R., additional, Solh, Melhem M., additional, Teshima, Takanori, additional, Urbano-Ispizua, Alvaro, additional, Verdonck, Leo F., additional, Gale, Robert Peter, additional, Hamilton, Betty K., additional, Majhail, Navneet S., additional, and Loren, Alison W., additional

Published
2018
Full Text
View/download PDF

140. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

Author

Smith, Sonali M., primary, Godfrey, James, additional, Ahn, Kwang Woo, additional, DiGilio, Alyssa, additional, Ahmed, Sairah, additional, Agrawal, Vaibhav, additional, Bachanova, Veronika, additional, Bacher, Ulrike, additional, Bashey, Asad, additional, Bolaños‐Meade, Javier, additional, Cairo, Mitchell, additional, Chen, Andy, additional, Chhabra, Saurabh, additional, Copelan, Edward, additional, Dahi, Parastoo B., additional, Aljurf, Mahmoud, additional, Farooq, Umar, additional, Ganguly, Siddhartha, additional, Hertzberg, Mark, additional, Holmberg, Leona, additional, Inwards, David, additional, Kanate, Abraham S., additional, Karmali, Reem, additional, Kenkre, Vaishalee P., additional, Kharfan‐Dabaja, Mohamed A., additional, Klein, Andreas, additional, Lazarus, Hillard M., additional, Mei, Matthew, additional, Mussetti, Alberto, additional, Nishihori, Taiga, additional, Ramakrishnan Geethakumari, Praveen, additional, Saad, Ayman, additional, Savani, Bipin N., additional, Schouten, Harry C., additional, Shah, Nirav, additional, Urbano‐Ispizua, Alvaro, additional, Vij, Ravi, additional, Vose, Julie, additional, Sureda, Anna, additional, and Hamadani, Mehdi, additional

Published
2018
Full Text
View/download PDF

141. Impact of Donor Type in Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation after Low-Dose TBI Based Conditioning: A Study From the Alwp of the Ebmt and Eurocord

Author

Baron, Frédéric, primary, Labopin, Myriam, additional, Ruggeri, Annalisa, additional, Cornelissen, Jan, additional, Meijer, Ellen, additional, Sengeloev, Henrik, additional, Niederwieser, Dietger, additional, de Groot, Marco R., additional, Schouten, Harry C., additional, Milpied, Noel, additional, Blaise, Didier, additional, Savani, Bipin N., additional, Gluckman, Eliane, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2018
Full Text
View/download PDF

142. No Benefit of Rituximab in Primary Central Nervous System Lymphoma Patients: Results of the Randomised Phase III HOVON 105 / ALLG NHL 24 Intergroup Study

Author

Bromberg, J.E.C, primary, Issa, Samar, additional, Bakunina, Katerina, additional, Minnema, Monique C., additional, Seute, Tatjana, additional, Durian, Marc, additional, Cull, Gavin, additional, Schouten, Harry C., additional, Stevens, Wendy B.C., additional, Zijlstra, Josee M., additional, Baars, Joke W., additional, Nijland, Marcel, additional, Mason, Kylie D., additional, Beeker, Aart, additional, van den Bent, Martin J., additional, Beijert, M., additional, Gonzales, Michael, additional, de Jong, Daphne, additional, and Doorduijn, Jeanette K., additional

Published
2018
Full Text
View/download PDF

143. Screening for platelet function disorders with Multiplate and platelet function analyzer

Author

Moenen, Floor C. J. I., primary, Vries, Minka J. A., additional, Nelemans, Patricia J., additional, van Rooy, Katrien J. M., additional, Vranken, Jeannique R. R. A., additional, Verhezen, Paul W. M., additional, Wetzels, Rick J. H., additional, ten Cate, Hugo, additional, Schouten, Harry C., additional, Beckers, Erik A. M., additional, and Henskens, Yvonne M. C., additional

Published
2017
Full Text
View/download PDF

144. Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission

Author

Versluis, Jurjen, primary, Kalin, Burak, additional, Zeijlemaker, Wendelien, additional, Passweg, Jakob, additional, Graux, Carlos, additional, Manz, Markus G., additional, Vekemans, Marie-Christiane, additional, Biemond, Bart J., additional, Legdeur, Marie-Cecile J.C., additional, Kooy, Marinus van Marwijk, additional, de Weerdt, Okke, additional, Wijermans, Pierre W., additional, Hoogendoorn, Mels, additional, Bargetzi, Mario J., additional, Kuball, Juergen, additional, Schouten, Harry C., additional, van der Velden, Vincent H.J., additional, Janssen, Jeroen J.W.M., additional, Pabst, Thomas, additional, Lowenberg, Bob, additional, Jongen-Lavrencic, Mojca, additional, Schuurhuis, Gerrit Jan, additional, Ossenkoppele, Gert, additional, and Cornelissen, Jan J., additional

Published
2017
Full Text
View/download PDF

145. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms : an analysis by the MPN QOL International Working Group

Author

Geyer, Holly L., Kosiorek, Heidi, Dueck, Amylou C., Scherber, Robyn, Slot, Stefanie, Zweegman, Sonja, te Boekhorst, Peter A. W., Senyak, Zhenya, Schouten, Harry C., Sackmann, Federico, Kerguelen Fuentes, Ana, Hernandez-Maraver, Dolores, Pahl, Heike L., Griesshammer, Martin, Stegelmann, Frank, Doehner, Konstanze, Lehmann, Thomas, Bonatz, Karin, Reiter, Andreas, Boyer, Francoise, Etienne, Gabriel, Ianotto, Jean-Christophe, Ranta, Dana, Roy, Lydia, Cahn, Jean-Yves, Harrison, Claire N., Radia, Deepti, Muxi, Pablo, Maldonado, Norman, Besses, Carlos, Cervantes, Francisco, Johansson, Peter L., Barbui, Tiziano, Barosi, Giovanni, Vannucchi, Alessandro M., Paoli, Chiara, Passamonti, Francesco, Andreasson, Bjorn, Ferrari, Maria L., Rambaldi, Alessandro, Samuelsson, Jan, Cannon, Keith, Birgegård, Gunnar, Xiao, Zhijian, Xu, Zefeng, Zhang, Yue, Sun, Xiujuan, Xu, Junqing, Kiladjian, Jean-Jacques, Zhang, Peihong, Gale, Robert Peter, Mesa, Ruben A., Geyer, Holly L., Kosiorek, Heidi, Dueck, Amylou C., Scherber, Robyn, Slot, Stefanie, Zweegman, Sonja, te Boekhorst, Peter A. W., Senyak, Zhenya, Schouten, Harry C., Sackmann, Federico, Kerguelen Fuentes, Ana, Hernandez-Maraver, Dolores, Pahl, Heike L., Griesshammer, Martin, Stegelmann, Frank, Doehner, Konstanze, Lehmann, Thomas, Bonatz, Karin, Reiter, Andreas, Boyer, Francoise, Etienne, Gabriel, Ianotto, Jean-Christophe, Ranta, Dana, Roy, Lydia, Cahn, Jean-Yves, Harrison, Claire N., Radia, Deepti, Muxi, Pablo, Maldonado, Norman, Besses, Carlos, Cervantes, Francisco, Johansson, Peter L., Barbui, Tiziano, Barosi, Giovanni, Vannucchi, Alessandro M., Paoli, Chiara, Passamonti, Francesco, Andreasson, Bjorn, Ferrari, Maria L., Rambaldi, Alessandro, Samuelsson, Jan, Cannon, Keith, Birgegård, Gunnar, Xiao, Zhijian, Xu, Zefeng, Zhang, Yue, Sun, Xiujuan, Xu, Junqing, Kiladjian, Jean-Jacques, Zhang, Peihong, Gale, Robert Peter, and Mesa, Ruben A.

Abstract

The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications and profound impact on quality of life. The role gender plays in the symptomatology of myeloproliferative neoplasms remains under-investigated. In this study we evaluated how gender relates to patients' characteristics, disease complications and overall symptom expression. A total of 2,006 patients (polycythemia vera=711, essential thrombocythemia=830, myelofibrosis=460, unknown=5) were prospectively evaluated, with patients completing the Myeloproliferative Neoplasm-Symptom Assessment Form and Brief Fatigue Inventory Patient Reported Outcome tools. Information on the individual patients' characteristics, disease complications and laboratory data was collected. Consistent with known literature, most female patients were more likely to have essential thrombocythemia (48.6% versus 33.0%; P<0.001) and most male patients were more likely to have polycythemia vera (41.8% versus 30.3%; P<0.001). The rate of thrombocytopenia was higher among males than females (13.9% versus 8.2%; P<0.001) and males also had greater red-blood cell transfusion requirements (7.3% versus 4.9%; P=0.02) with shorter mean disease duration (6.4 versus 7.2 years, P=0.03). Despite there being no statistical differences in risk scores, receipt of most therapies or prior complications (hemorrhage, thrombosis), females had more severe and more frequent symptoms for most individual symptoms, along with overall total symptom score (22.8 versus 20.3; P<0.001). Females had particularly high scores for abdominal-related symptoms (abdominal pain/discomfort) and microvascular symptoms (headache, fatigue, insomnia, concentration difficulties, dizziness; all P<0.01). Despite complaining of more severe symptom burden, females had similar quality of life scores to those of males. The results of this study

Published
2017
Full Text
View/download PDF

146. Therapeutic value of clofarabine in younger and middle aged (18 - 65 yrs) adults with newly diagnosed AML.

Author

UCL - SSS/IREC/MONT-Pôle Mont Godinne, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/MEXP - Médecine expérimentale, UCL - (MGD) Service d'hématologie, UCL - (SLuc) Service d'hématologie, Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, van Norden, Yvette, Biemond, Bart J, Schouten, Harry C, Spertini, Olivier, Vellenga, Edo, Graux, Carlos, Havelange, Violaine, de Greef, Georgine E, de Weerdt, Okke, Legdeur, Marie-Cecile J C, Kuball, Juergen, van Marwijk Kooy, Marinus, Gjertsen, Bjorn T, Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A, van Lammeren-Venema, Daniëlle, Hodossy, Beata, Breems, Dimitri A, Chalandon, Yves, Passweg, Jakob, Valk, Peter J M, Manz, Markus G, Ossenkoppele, Gert J, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), UCL - SSS/IREC/MONT-Pôle Mont Godinne, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/MEXP - Médecine expérimentale, UCL - (MGD) Service d'hématologie, UCL - (SLuc) Service d'hématologie, Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, van Norden, Yvette, Biemond, Bart J, Schouten, Harry C, Spertini, Olivier, Vellenga, Edo, Graux, Carlos, Havelange, Violaine, de Greef, Georgine E, de Weerdt, Okke, Legdeur, Marie-Cecile J C, Kuball, Juergen, van Marwijk Kooy, Marinus, Gjertsen, Bjorn T, Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A, van Lammeren-Venema, Daniëlle, Hodossy, Beata, Breems, Dimitri A, Chalandon, Yves, Passweg, Jakob, Valk, Peter J M, Manz, Markus G, Ossenkoppele, Gert J, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), and Swiss Group for Clinical Cancer Research (SAKK)

Abstract

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be critically evaluated in younger adults in the frontline with standard chemotherapy. We compared two induction regimens in newly diagnosed patients aged 18-65 with AML/high risk MDS, i.e., idarubicine-cytarabine (cycle I) and amsacrine-cytarabine (cycle II) without or with clofarabine (10 mg/m(2) on days 1-5 of each of both cycles). Consolidation involved chemotherapy with or without hematopoietic stem cell transplantation. Event free survival (EFS, primary endpoint) and other clinical endpoints and toxicities were assessed. 402 and 393 evaluable patients were randomized to the control or clofarabine induction treatment arms. Complete remission rates (89%) did not differ but were attained faster with clofarabine (66% versus 75% after cycle I). Clofarabine added grade III-IV toxicities, and delayed hematological recovery. At a median follow up of 36 months, the study reveals no differences in overall survival and EFS between the control (EFS 35% ±3 (SE) at 4 years) and clofarabine treatments (38% ±3) but a markedly reduced relapse rate (44% ± 3 versus 35% ± 3) in favor of clofarabine and an increased death probability in remission (15% ±2 versus 22% ±3). In the subgroup analyses, clofarabine improved OS and EFS for European-Leukemia-Net ELN 2010 Intermediate-I prognostic risk AML (EFS 26 % ±4 versus 40% ±5 at 4 years, Cox-P=0.002) and for the intermediate risk genotype NPM1wild type/FLT3 without internal-tandem-duplications (EFS 18% ±5 versus 40% ±7, Cox- P<0.001). Clofarabine improves survival in subsets of intermediate-risk AML only.

Published
2017

147. Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission.

Author

UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Versluis, Jurjen, Kalin, Burak, Zeijlemaker, Wendelien, Passweg, Jakob, Graux, Carlos, Manz, Markus G, Vekemans, Marie-Christiane, Biemond, Bart J, Legdeur, Marie-Cecile J C, Kooy, Marinus van Marwijk, de Weerdt, Okke, Wijermans, Pierre W, Hoogendoorn, Mels, Bargetzi, Mario J, Kuball, Juergen, Schouten, Harry C, van der Velden, Vincent H J, Janssen, Jeroen J W M, Pabst, Thomas, Lowenberg, Bob, Jongen-Lavrencic, Mojca, Schuurhuis, Gerrit Jan, Ossenkoppele, Gert, Cornelissen, Jan J, UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Versluis, Jurjen, Kalin, Burak, Zeijlemaker, Wendelien, Passweg, Jakob, Graux, Carlos, Manz, Markus G, Vekemans, Marie-Christiane, Biemond, Bart J, Legdeur, Marie-Cecile J C, Kooy, Marinus van Marwijk, de Weerdt, Okke, Wijermans, Pierre W, Hoogendoorn, Mels, Bargetzi, Mario J, Kuball, Juergen, Schouten, Harry C, van der Velden, Vincent H J, Janssen, Jeroen J W M, Pabst, Thomas, Lowenberg, Bob, Jongen-Lavrencic, Mojca, Schuurhuis, Gerrit Jan, Ossenkoppele, Gert, and Cornelissen, Jan J

Abstract

The detection of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) may improve future risk-adapted treatment strategies. We assessed whether MRD-positive and MRD-negative patients with AML benefit differently from the graft-versus-leukemia effect of allogeneic hematopoietic stem-cell transplantation (alloHSCT). A total of 1,511 patients were treated in subsequent Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research AML trials, of whom 547 obtained a first complete remission, received postremission treatment (PRT), and had available flow cytometric MRD before PRT. MRD positivity was defined as more than 0.1% cells with a leukemia-associated immunophenotype within the WBC compartment. PRT consisted of alloHSCT (n = 282), conventional PRT by a third cycle of chemotherapy (n = 160), or autologous hematopoietic stem-cell transplantation (n = 105). MRD was positive in 129 patients (24%) after induction chemotherapy before proceeding to PRT. Overall survival and relapse-free survival were significantly better in patients without MRD before PRT compared with MRD-positive patients (65% ± 2% 50% ± 5% at 4 years; = .002; and 58% ± 3% 38% ± 4%; < .001, respectively), which was mainly because of a lower cumulative incidence of relapse (32% ± 2% compared with 54% ± 4%; < .001, respectively). Multivariable analysis with adjustment for covariables showed that the incidence of relapse was significantly reduced after alloHSCT compared with chemotherapy or autologous hematopoietic stem cell transplantation (hazard ratio [HR], 0.36; < .001), which was similarly exerted in both MRD-negative and MRD-positive patients (HR, 0.38; < .001; and HR, 0.35; < .001, respectively). The graft-versus-leukemia effect of alloHSCT is equally present in MRD-positive and MRD-negative patients, which advocates a personalized application of alloHSCT, taking into account the risk of relapse determined by AML risk group and MRD status, as

Published
2017

148. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Author

Stamceltransplantatieteam, CTI Kuball, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, van Norden, Yvette, Biemond, Bart J., Schouten, Harry C., Spertini, Olivier, Vellenga, Edo, Graux, Carlos, Havelange, Violaine, de Greef, Georgine E, De Weerdt, Okke, Legdeur, Marie-Cecile J C, Kuball, Juergen, van Marwijk Kooy, Marinus, Gjertsen, Bjorn T, Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A, van Lammeren-Venema, Daniëlle, Hodossy, Beata, Breems, Dimitri A, Chalandon, Yves, Passweg, Jakob, Valk, Peter J M, Manz, Markus G, Ossenkoppele, Gert J, Stamceltransplantatieteam, CTI Kuball, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, van Norden, Yvette, Biemond, Bart J., Schouten, Harry C., Spertini, Olivier, Vellenga, Edo, Graux, Carlos, Havelange, Violaine, de Greef, Georgine E, De Weerdt, Okke, Legdeur, Marie-Cecile J C, Kuball, Juergen, van Marwijk Kooy, Marinus, Gjertsen, Bjorn T, Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A, van Lammeren-Venema, Daniëlle, Hodossy, Beata, Breems, Dimitri A, Chalandon, Yves, Passweg, Jakob, Valk, Peter J M, Manz, Markus G, and Ossenkoppele, Gert J

Published
2017

149. Improved survival after acute graft-versus-host disease diagnosis in the modern era.

Author

Khoury, Hanna J., Wang, Tao, Hemmer, Michael T., Couriel, Daniel, Alousi, Amin, Cutler, Corey, Aljurf, Mahmoud, Antin, Joseph H, Ayas, Mouhab, Battiwalla, Minoo, Cahn, Jean-Yves, Cairo, Mitchell, Chen, Yi-Bin, Gale, Robert Peter, Hashmi, Shahrukh, Hayashi, Robert J., Jagasia, Madan, Juckett, Mark, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Litzow, Mark, Majhail, Navneet, Miller, Alan, Nishihori, Taiga, Qayed, Muna, Schoemans, Helene, Schouten, Harry C., Socie, Gerard, Storek, Jan, Verdonck, Leo, Vij, Ravi, Wood, William A., Yu, Lolie, Martino, Rodrigo, Carabasi, Matthew, Dandoy, Christopher, Gergis, Usama, Hematti, Peiman, Solh, Melham, Jamani, Kareem, Lehmann, Leslie, Savani, Bipin, Schultz, Kirk R., Wirk, Baldeep M., Spellman, Stephen, Arora, Mukta, Pidala, Joseph, Khoury, Hanna J., Wang, Tao, Hemmer, Michael T., Couriel, Daniel, Alousi, Amin, Cutler, Corey, Aljurf, Mahmoud, Antin, Joseph H, Ayas, Mouhab, Battiwalla, Minoo, Cahn, Jean-Yves, Cairo, Mitchell, Chen, Yi-Bin, Gale, Robert Peter, Hashmi, Shahrukh, Hayashi, Robert J., Jagasia, Madan, Juckett, Mark, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Litzow, Mark, Majhail, Navneet, Miller, Alan, Nishihori, Taiga, Qayed, Muna, Schoemans, Helene, Schouten, Harry C., Socie, Gerard, Storek, Jan, Verdonck, Leo, Vij, Ravi, Wood, William A., Yu, Lolie, Martino, Rodrigo, Carabasi, Matthew, Dandoy, Christopher, Gergis, Usama, Hematti, Peiman, Solh, Melham, Jamani, Kareem, Lehmann, Leslie, Savani, Bipin, Schultz, Kirk R., Wirk, Baldeep M., Spellman, Stephen, Arora, Mukta, and Pidala, Joseph

Abstract

A cute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-versus-host disease. We examined outcome following diagnosis of grade II-IV acute graft-versus-host disease according to time period, and explored effects according to original graft-versus-host disease prophylaxis regimen and maximum overall grade of acute graft-versus-host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft-versus-host disease (n=497 for 1999-2001, n=962 for 2002-2005, n=1,446 for 2006-2010). The median (range) follow-up was 144 (4-174), 97 (4-147) and 60 (8-99) months for 1999-2001, 2002-2005, and 2006-2010, respectively. Among the cohort with grade II-IV acute graft-versus-host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999-2001, 2002-2005, and 2006-2012, respectively (P

Published
2017

150. Symptomatic profiles of 1334 polycythemia vera patients: implications of inadequately controlled disease

Author

Geyer, Holly L., Scherber, Robyn, Kosiorek, Heidi, Dueck, Amylou C., Kiladjian, Jean-Jacques, Xiao, Zhijian, Slot, Stefanie, Zweegman, Sonja, Sackmann, Federico, Kerguelen Fuentes, Ana, Hernández-Maraver, Dolores, Döhner, Konstanze, Harrison, Claire N., Radia, Deepti, Muxi, Pablo, Besses, Carlos, Cervantes Requena, F., Johansson, Peter L., Andreasson, Bjorn, Rambaldi, Alessandro, Barbui, Tiziano, Bonatz, Karin, Reiter, Andreas, Boyer, Francoise, Etienne, Gabriel, Ianotto, Jean-Christophe, Ranta, Dana, Roy, Lydia, Cahn, Jean-Yves, Maldonado, Norman, Barosi, Giovanni, Ferrari, Maria L., Gale, Robert Peter, Birgegard, Gunnar, Xu, Zefeng, Zhang, Yue, Sun, Xiujuan, Xu, Junqing, Zhang, Peihong, Te Boekhorst, Peter A., Commandeur, Suzan, Schouten, Harry C., Pahl, Heike L., Griesshammer, Martin, Stegelmann, Frank, Lehmann, Thomas, Senyak, Zhenya, Vannucchi, Alessandro M., Passamonti, Francesco, Samuelsson, Jan, Mesa, Ruben A., and Universitat de Barcelona

Subjects
Oncologia, Oncology, Medul·la òssia, Malalties hematològiques, Hematologic diseases, Bone marrow, Hematology, Hematologia
Abstract

Purpose Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and a heightened risk of life-threatening complications. Recent studies have demonstrated the effectiveness of JAK inhibitor therapy in patients with PV patients who have a history of prior hydroxyurea (HU) use (including resistance or intolerance), phlebotomy requirements, and palpable splenomegaly. We aimed to determine how these features contribute alone and in aggregate to the PV symptom burden. Patients and Methods Through prospective evaluation of 1,334 patients with PV who had characterized symptom burden, we assessed patient demographics, laboratory data, and the presence of splenomegaly by disease feature (ie, known HU use, known phlebotomy requirements, splenomegaly). Results The presence of each feature in itself is associated with a moderately high symptom burden (MPN symptom assessment form [SAF] total symptom score [TSS] range, 27.7 to 29.2) that persists independent of PV risk category. In addition, symptoms incrementally increase in severity with the addition of other features. Patients with PV who had all three features (PV-HUPS) faced the highest total score (MPN-SAF TSS, 32.5) but had similar individual symptom scores to patients with known HU use (PV-HU), known phlebotomy (PV-P), and splenomegaly (PV-S). Conclusion The results of this study suggest that patients with PV who have any one of the features in question (known HU use, known phlebotomy, or splenomegaly) have significant PV-associated symptoms. Furthermore, it demonstrates that many PV symptoms remain severe independent of the number of features present.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results